Press Releases

First cystic fibrosis patient in Phase 1b study successfully completed two administrations of ARCT-032 On track to share interim Phase 1b data in H1 2024 SAN DIEGO --(BUSINESS WIRE)--Nov. 27, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage

Expected cash runway extended to the end of 2026 $35 million milestone achieved under CSL collaboration ARCT-154 remains on track for Japan-NDA approval in December Enrollment target reached in Phase 3 bivalent COVID vaccine comparison trial Enrollment initiated in ARCT-032 Phase 1b study; dosing

SAN DIEGO --(BUSINESS WIRE)--Oct. 25, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

SAN DIEGO --(BUSINESS WIRE)--Oct. 23, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare

$165 million in manufacturing grants awarded to ARCALIS by the Japanese government SAN DIEGO --(BUSINESS WIRE)--Oct. 4, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of

CF Foundation Increases Financial Commitment to ~$25 Million SAN DIEGO --(BUSINESS WIRE)--Sep. 26, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease

Late-breaking data presented at 9 th   ESWI Influenza Conference in Valencia SAN DIEGO --(BUSINESS WIRE)--Sep. 19, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of

EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response compared to Comirnaty® and superiority of ARCT-154 in neutralizing antibody response against SARS-CoV-2

SAN DIEGO --(BUSINESS WIRE)--Aug. 17, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare

LUNAR-FLU collaboration with CSL Seqirus achieves additional $17.5 million development milestone SAN DIEGO --(BUSINESS WIRE)--Aug. 14, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the